In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may ...

Benzinga is an innovative financial news outlet that has become the first choice for brokerages given its easy-to-integrate API suite and easy-to-consume content. Benzinga provides timely, actionable ...

Merck & Co., Inc. MRK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Organon, which was spun-off from Merck (MRK.N), opens new tab in 2021, will make an upfront payment of $175 million, as well as payments of $75 million and up to $950 million upon achievement of ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...